The therapy targets the fuel used to nourish tumors, according to a July 15 news release from the Yale Cancer Center.
The technique acts as a Trojan horse by attaching cancer drugs to nucleic acid released from dying cells inside growing tumors. The drug then crosses the tumor’s membrane as live cancer cells pull the nucleic acid into the tumor with the cancer drug attached. The drug, called an antinuclear antibody-drug conjugate, can then begin to attack the tumor from the inside.
“A likely welcome effect of this very targeted therapy is a reduction in toxic side effects experienced by patients when less precise therapies kill off healthy tissue,” the release said.
At the Becker's Perioperative Summit, taking place October 29–31 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
